FDANews
FDAnews Drug Daily Bulletin

Pfizer Study: No Link Between Chantix and Psychosis

May 2, 2016

A Pfizer study evaluating Chantix and bupropion met its primary safety endpoint of no significant increase in neuropsychiatric adverse events.

The EAGLES trial, which evaluated 8,144 adult smokers, compared Chantix and bupropion with placebo and nicotine patch in adult smokers with and without a history of psychiatric disorders.

The occurrence of neuropsychiatric adverse events in patients without a history of psychiatric disorders was 1.3 percent, and 6.5 percent in patients with a history.

 

View More Stories